The role of NF-kappaB in lymphoid malignancies.
Nuclear Factor kappaB (NF-kappaB) transcription factors are central regulators of lymphocyte proliferation, survival and development. Although normally subject to tight control, constitutive activation of NF-kappaB promotes inappropriate lymphocyte survival and proliferation, and is recognised as key pathological feature in various lymphoid malignancies. Inhibition of NF-kappaB may be an attractive therapeutic approach in these diseases. This review focuses on the mechanisms and functional consequences of NF-kappaB activation in lymphoid malignancies and potential therapeutic strategies for inhibition of NF-kappaB.
Packham
Graham
G
Cancer Research UK Clinical Centre, Cancer Sciences Division, University of Southampton School of Medicine, Southampton General Hospital, Southampton, SO16 6YD, UK. gpackham@soton.ac.uk
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002470:Cell Survival; D006801:Humans; D007938:Leukemia / Q000276:immunology / Q000378:metabolism*; D008213:Lymphocyte Activation; D008223:Lymphoma / Q000276:immunology / Q000378:metabolism*; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology*
D000970:Antineoplastic Agents; D016328:NF-kappa B